US IPO Market Contracts as Returns Slump in the Third Quarter The IPO market slowed in the 3Q 2015 to 34 deals, down 43% year-over-year, hurt by the broad market sell-off and specific sector conditions, including a near absence of tech and energy...read more
Global Blood Therapeutics became the fifth IPO of 2015 to pop more than 100% on its first day. Year-to-date, 130 IPOs have raised $22 billion, or 31% fewer IPOs...read more
Global Blood Therapeutics, an early-stage biotech developing a small molecule therapy for sickle cell disease, raised $120 million by offering 6.0 million shares at $20, above the range of $16 to $18. Global Blood Therapeutics plans to list on the Nasdaq under...read more
It's the final push for US IPOs before a four-week lull that should end in mid-September. Five IPOs are on the calendar this week, plus two blank check companies. Sickle cell...read more
Renaissance Capital's 3Q 2015 Quarterly US IPO Market Review
US IPO Market Contracts as Returns Slump in the Third Quarter The IPO market slowed in the 3Q 2015 to 34 deals, down 43% year-over-year, hurt by the broad market sell-off and specific sector conditions, including a near absence of tech and energy...read more
US IPO Weekly Recap: Sickle cell biotech pops 100% and investment bank goes public
Global Blood Therapeutics became the fifth IPO of 2015 to pop more than 100% on its first day.
Year-to-date, 130 IPOs have raised $22 billion, or 31% fewer IPOs...read more
Hot blooded: Global Blood Therapeutics prices IPO above the range at $20
Global Blood Therapeutics, an early-stage biotech developing a small molecule therapy for sickle cell disease, raised $120 million by offering 6.0 million shares at $20, above the range of $16 to $18. Global Blood Therapeutics plans to list on the Nasdaq under...read more
Week ahead: 5 IPOs set to price during the week of August 10
It's the final push for US IPOs before a four-week lull that should end in mid-September. Five IPOs are on the calendar this week, plus two blank check companies. Sickle cell...read more